Last update 30 Jun 2024

Paritaprevir

Last update 30 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, Paritaprevir (USAN/INN), Veruprevir

+ [3]

Target

NS3/NS4A

Mechanism

NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Chronic hepatitis C genotype 1Chronic hepatitis C genotype 3Hepatitis C+ [1]

Originator Organization

Enanta Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Enanta Pharmaceuticals, Inc.

Abbott Laboratories

AbbVie, Inc.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC40H43N7O7S

InChIKeyUAUIUKWPKRJZJV-QPLHLKROSA-N

CAS Registry1216941-48-8

Clinical Trials associated with Paritaprevir

JPRN-UMIN000026640 / CompletedIIT

Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients - Virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients

Start Date16 Jan 2017

Sponsor / Collaborator-

JPRN-UMIN000022563 / Unknown statusIIT

The efficacy of paritaprevir and ombitasvir with a booster dose of ritonavir in genotype 1 HCV patients with hemodialysis - Viek-tory HD study

Start Date01 Jun 2016

Sponsor / Collaborator

Mitsui Memorial Hospital

JPRN-UMIN000020911 / RecruitingIIT

The effects of IFN-free 2D regimen (ombitasvir/paritaprevir/ritonavir) on host immune responses against hepatitis C virus - The effect of HCV elimination on host immune responces against hepatitis C virus

Start Date05 Mar 2016

Sponsor / Collaborator

Kanazawa University Hospital

100 Clinical Results associated with Paritaprevir

100 Translational Medicine associated with Paritaprevir

100 Patents (Medical) associated with Paritaprevir

592

Literatures (Medical) associated with Paritaprevir

01 Apr 2024·Biochimica et biophysica acta. General subjects

FBXO8 is a novel prognostic biomarker in different molecular subtypes of breast cancer and suppresses breast cancer progression by targeting c-MYC

Article

Author: Zhang, Feng ; Man, Shad ; Khan, Abdul Jamil ; Abbas, Manzar ; Liu, Shihao

F-box only protein 8 (FBXO8) is a recently identified member of the F-box proteins, showcasing its novelty in this protein family. Extensive research has established FBXO8's role as a tumor suppressor in various cancers, including hepatocellular carcinoma, and colorectal cancer, Nevertheless, its functional, mechanistic, and prognostic roles in primary and metastatic breast cancer, particularly in different molecular subtypes of breast cancer, various stages, as well as its potential implications in immunotherapy, tumor microenvironment, and prognostic survival among breast cancer patients, remain unexplored. In this article, we employed a multi-dimensional investigation leveraging TCGA, TIMER, TISIDB, STRING, MEXPRESS, UALCAN, and cBioPortal databases to explore the underlying suppression mechanism of FBXO8 in breast cancer. FBXO8 negatively correlates with MYC, NOTCH, WNT and inflammatory signaling pathways in breast tumor microenvironment. Furthermore we conducted RT-PCR, western blot, cell proliferation, cell migration, and mRNA target gene RT-PCR analyses to elucidate the role of FBXO8 in breast cancer progression. Mechanistically, PTEN and FBXW7 expression were down-regulated and MYC, IL10, IL6, NOTCH1, WNT6 mRNA expressions were up-regulated in FBXO8 knockdown cell lines. c-MYC silenced cells showed an increase in FBXO8 protein level, which suggests a negative feedback loop between FBXO8 and c-MYC to control breast cancer metastasis. These findings illuminate the novel role of FBXO8 as a prognostic and therapeutic target across different molecular subtypes of breast cancer. Finally, through the utilization of virtual screening and Molecular Dynamics simulations, we successfully identified two FDA-approved medications, Ledipasvir and Paritaprevir, that demonstrated robust binding capabilities and interactions with FBXO8.

01 Oct 2023·Gastroenterologia y hepatologia

Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

Article

Author: Roget, Mercé ; García-Samaniego, Javier ; Buti, Maria ; Rodríguez, Manuel ; Carmona, Isabel ; Azancot, María A ; Delgado, Manuel ; Rodríguez-Frías, Francisco ; Purchades, Laura ; Losa-García, Juan E ; Riveiro-Barciela, Mar ; Prieto, Martín ; Muñoz-Gómez, Raquel ; Gutiérrez, María L ; Morano, Luís ; Escudero-García, Desamparados ; Martín-Granizo, Ignacio ; Serra, Miguel Ángel ; Montero-Alonso, Marta ; Ramos, Natalia ; Londoño, María-Carlota ; Martínez-Campreciós, Joan

BACKGROUND AND AIM:

Patients with chronic kidney disease (CKD) and hepatitis C infection can be safely and effectively treated with direct-acting antivirals (DAAs). However, there is scarce data on the long-term impact of hepatitis C cure on CKD. The aim of this study was to assess the long-term mortality, morbidity and hepatic/renal function outcomes in a cohort of HCV-infected individuals with CKD treated with DAAs.

METHODS:

135 HCV patients with CKD stage 3b-5 who received ombitasvir/paritaprevir/ritonavir±dasabuvir in a multicenter study were evaluated for long-term hepatic and renal outcomes and their associated mortality.

RESULTS:

125 patients achieved SVR and 66 were included. Prior to SVR, 53 were under renal replacement therapy (RRT) and 25 (37.8%) had liver cirrhosis. After a follow-up of 4.5 years, 25 (38%) required kidney transplantation but none combined liver-kidney. No changes in renal function were observed among the 51 patients who did not receive renal transplant although eGFR values improved in those with baseline CKD stage 3b-4. Three (5.6%) subjects were weaned from RRT. Eighteen (27.3%) patients died, mostly from cardiovascular events; 2 developed liver decompensation and 1 hepatocellular carcinoma. No HCV reinfection was observed.

CONCLUSIONS:

Long-term mortality remained high among end-stage CKD patients despite HCV cure. Overall, no improvement in renal function was observed and a high proportion of patients required kidney transplantation. However, in CKD stage 3b-4 HCV cure may play a positive role in renal function.

bioRxiv : the preprint server for biology

Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED

Author: Danelius, E ; Bu, G ; Gonen, T ; Wieske, L H

Abstract:

Paritaprevir is an orally bioavailable, macrocyclic drug used for treating chronic Hepatitis C virus infection. Its structures had been elusive to the public until recently when one of the crystal forms was solved by MicroED. In this work, we report the MicroED structures of two distinct polymorphic crystal forms of paritaprevir from the same experiment. The different polymorphs show conformational changes in the macrocyclic core, as well as the cyclopropylsulfonamide and methylpyrazinamide substituents. Molecular docking shows that one of the conformations fits well into the active site pocket of the NS3/4A serine protease target, and can interact with the pocket and catalytic triad via hydrophobic interactions and hydrogen bonds. These results can provide further insight for optimization of the binding of acylsulfonamide inhibitors to the NS3/4A serine protease. In addition, this also demonstrate the opportunity of deriving different polymorphs and distinct macrocycle conformations from the same experiments using MicroED.

News (Medical) associated with Paritaprevir

30 Apr 2021

·www.biospace.com

Research Roundup: Underlying Conditions, COVID-19 Severity and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones. More Data on Underlying Conditions and COVID-19 Severity A study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance Centre (HPSC) in Ireland has further defined the association between comorbidities and poor outcomes with COVID-19. The study took place between March and July 2020 and collected national data in Ireland from both hospital and community settings. It collected data for almost 20,000 confirmed cases of COVID-19. The results were published in The Lancet Regional Health – Europe. Of the patients studied, there were 1,476 deaths, 2,811 hospitalizations, and 438 ICU admissions. The conditions that carried the most risk were chronic heart disease, a chronic neurological condition, chronic kidney disease and cancer. Morbid obesity was also identified as being associated with severe outcomes. “Previous studies conducted have suggested that specific underlying conditions influence adverse health outcomes among those with a confirmed diagnosis of COVID-19,” said Kathleen Bennett, associate professor in Biostatistics, RCSI. “However, the majority of these studies have focused on hospital-based or local populations only. This study is the first population-based research to capture data across all settings in Ireland, including both community and hospital settings and so it gives us a better picture of the impact of the disease on patients at the population level.” Gilead’s Remdesivir Plus Hep C Drugs Effective Against COVID-19 Researchers with Mount Sinai Hospital and Mount Sinai School of Medicine tested a combination of Gilead’s remdesivir, an antiviral drug, with repurposed drugs for hepatitis C virus (HCV). The combinations, they found, were 10-times more effective at inhibiting SARS-CoV-2, the virus behind COVID-19. Four HCV drugs in combination with remdesivir improved the efficacy of remdesivir. They were simeprevir, vaniprevir, paritaprevir, and grazoprevir. The research group tested 10 HCV drugs, some already approved by the U.S. Food and Drug Administration (FDA). They utilized a supercomputer to model how drugs bind to viral proteins and predicted that those 10 would bind tightly to the SARS-CoV-2 Main protease (Mpro). They also found that seven of the drugs inhibited the SARS-CoV-2 protease. They then tested the seven drugs in monkey and human cells in culture. Four of the HCV drugs inhibited a different SARS-CoV-2 protease called PLpro. It was the four drugs that targeted PLpro that increased the efficacy of remdesivir by as much as 10-fold. While remdesivir must be dosed intravenously, the four HCV drugs are oral. Type 2 Diabetes Associated with Muscle Gene Researchers at Lund University found that in type 2 diabetes, a specific gene related to muscle cells is less active than it is in other people. The gene, VPS39, is important for when muscle cells absorb sugar from blood and build new muscle. In type 2 diabetes, the body’s ability to generate insulin is impaired, resulting in chronically increased blood sugar. The muscles are generally worse at absorbing sugar from food, and this muscle function and strength are typically impaired in type 2 diabetic patients. Their study, which was on muscle stem cells in type 2 diabetes patients compared to healthy controls, found that there were more than twice as many epigenetic changes in the type 2 diabetes group during the differentiation from muscle stem cell to mature muscle cells. Muscle-specific genes were not regulated normally, and epigenetics did not appear to function in the same way in cells from people with type 2 diabetes did. How Brain Cells in Alzheimer’s Patients Lose Their Identity Investigators with the Salk Institute grew neurons that resemble better than ever before the brain cells in older patients. It appears to have given them insight into how the brain cells go off-track in Alzheimer’s patients, losing their cellular identity. The brain cells were characterized by markers of stress in addition to changes where the cells become less specialized. This is similar to what has been observed in cancer cells. The researchers collected skin cells from 13 sporadic, age-related Alzheimer’s patients, as well as cells from three people with the rarer, inherited form of Alzheimer’s. Their controls were skin cells from 19 people age-matched but without Alzheimer’s. Using fibroblasts, they induced neurons, then compared the molecular differences in the cells. They found that the cells from people with Alzheimer’s had specific characteristics different from the healthy control cells. The Alzheimer’s cells lacked synaptic structures, which are vital to sending signals to each other. There were also changes in signaling pathways, which control cell function, an indication the cells were under stress. They also found that the induced Alzheimer’s neurons had similar molecular signatures to immature nerve cells found in the developing brain. What this was interpreted to mean was the Alzheimer’s-based cells had lost their mature identity. A New Anti-Aging Compound Scientists at Washington University School of Medicine found a natural compound, nicotinamide mononucleotide (NMN), that in earlier studies seemed to counteract aging and improved metabolic health in mice, also had positive clinical effects in people. They conducted a clinical trial of postmenopausal women with prediabetes. They demonstrated that NMN improved the ability of insulin to increase glucose uptake in skeletal muscle. This ability is often abnormal in obese, prediabetic or type 2 diabetics. NMN improved expression of genes involved in muscle structure are remodeling. However, it did not lower blood sugar levels, blood pressure, improve blood lipids, increase insulin sensitivity in the liver, reduce fat in the liver or decrease circulating markers of inflammation as was observed in mice. “Although our study shows a beneficial effect of NMN in skeletal muscle, it is premature to make any clinical recommendations based on the results from our study,” said Samuel Klein, senior investigator and the William H. Danforth Professor of Medicine and Nutritional Science and director of the Center for Human Nutrition. “Normally, when a treatment improves insulin sensitivity in skeletal muscle, as is observed with weight loss or some diabetes medications, there also are related improvement in other markers of metabolic health, which we did not detect in our study participants.”

04 Apr 2012

·www.biospace.com

Enanta Pharmaceuticals, Inc. Announces Positive Phase 2 Results From Interferon-Free Combination Studies With ABT-450 for Hepatitis C Treatment to be Presented at EASL

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Oral presentations will discuss Phase 2 results from "Pilot" and "Co-Pilot", which investigated two different interferon-free combination regimens containing ABT-450, the lead candidate from Enanta's collaborative HCV protease inhibitor program with Abbott. ABT-450 will be included in two additional poster presentations and a third poster presentation will report in vitro data from Enanta's proprietary nucleotide HCV polymerase inhibitor program. Abstracts are available at . Phase 2 Data Highlights In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 93 percent and 95 percent of treatment-naive genotype 1 (GT1) patients. In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r. In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment. In a separate study, known as "Pilot", 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24). "The results from Pilot and Co-Pilot showed very encouraging levels of sustained response and suggest that ABT-450 could be an important component in new interferon-free, all-oral regimens for previously treated and treatment-naive patients with HCV," said Jay Luly, Ph.D., President and CEO of Enanta. "Enanta's involvement in five distinct HCV drug classes provides multiple avenues to pursue our goal of bringing to patients innovative therapies that are safer and more effective than current treatments." Oral Presentations Oral Presentation, Eric Lawitz et al.; Thursday, April 19, 16:00-18:00 CET / 10:00 am - 12:00 pm EDT. A 12-week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naive HCV IL28B-CC Genotype-1-Infected Subjects The objectives of the 12-week, phase 2 study were to assess the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450/r 150/100 mg QD and ABT-072 400 mg QD + ribavirin administered for 12 weeks. The study was conducted in 11 treatment naive adults from multiple ethnic backgrounds with non-cirrhotic HCV GT1 (8 GT 1a, 3 GT 1b). Ribavirin 1000-1200 mg/day was weight-based and dosed twice daily. The primary endpoint was percentage of patients with HCV RNA <25 IU/ml from week 4 through 12. Other trial endpoints include early virologic response, RVR and SVR through 24 weeks. 100 percent of patients maintained HCV RNA levels <25 IU/mL from weeks 4 through 12 of treatment, and all had undetectable HCV RNA from week 5 to the end of treatment. 91 percent of patients achieved SVR24, In the trial, the most common adverse events reported were headache, fatigue, nausea and dry skin. There were no premature discontinuations. Late-Breaking Oral Presentation, Fred Poordad, et al.; Saturday, April 21, 15:30-17:30 CET / 9:30-11:30 am EDT. 12-Week Interferon-Free Regimen of ABT-450/r+ABT-333+Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naive HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders The objectives of this phase 2 study were to assess safety and tolerability 12-week interferon-free regimens in HCV GT1 patients who were either treatment naive or previous non-responders. The trial had three arms with three primary end points rapid virological response (RVR) at week 4 and SVR at weeks 4 and 12. Enrollment was open to GT1-infected patients regardless of IL28B host genotype and ribavirin dosing was weight-based. 95 percent (18 of 19) of treatment-naive patients infected with HCV GT1 (17 GT 1a, 2 GT 1b) achieved SVR12 with ABT 450/r 250/100 mg dosed once daily (QD) +ABT-333 400 mg dosed twice daily (BID) + ribavirin (Arm 1). 93 percent (13 of 14) of treatment- naive patients infected with HCV GT1 (11 GT 1a, 3 GT1b) achieved SVR12 with ABT 450/r 150/100 mg QD +ABT-333 400 mg BID + ribavirin (Arm 2). 47 percent (8 of 17) of patients with HCV GT1 (16 GT1a, 1 GT1b) who had previously not responded to other HCV treatments achieved SVR12 with ABT 450/r 150/100 mg QD +ABT-333 400 mg BID + ribavirin (Arm 3). One patient in Arm 1 discontinued due to asymptomatic isolated ALT/AST elevations at week 2. One patient in Arm 2 discontinued due to noncompliance in week 1. All remaining patients in Arms 1 and 2 completed treatment and achieved SVR12. In Arm 3, six patients experienced viral breakthrough while on treatment and three patients relapsed after treatment stopped. In the trial the most common adverse events were fatigue (42 percent), nausea (22 percent) and headache (20 percent). Abbott is developing ABT-450 with low dose ritonavir (ABT-450/r) which enhances the pharmacokinetic properties of ABT-450, allowing for once daily dosing. The use of ritonavir 100 mg with ABT-450 for the treatment of HCV is investigational. Poster Presentations Poster #867, Tami Pilot-Matias et al.; Friday, April 20 (11:00-11:30, 12:30-14:00, 15:30-16:00 CET) "In vitro combinatory effect of HCV NS3/4A protease inhibitor ABT-450, NS5A inhibitor ABT-267, and non-nucleoside NS5B polymerase inhibitor ABT-333" Poster #1187, Eric Lawitz et al; Saturday, April 21 (11:00-11:30, 12:30-13:30, 15:00-15:30 CET) "ABT-450/ritonavir (ABT-450/r) combined with pegylated interferon alpha-2a/ribavirin after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results" Poster #1200, Christopher M. Owens et al.; Saturday, April 21 (11:00 11:30, 12:30 13:30, 15:00 15:30 CET) "Antiviral Activity of EP-NI266, a Potent Nucleotide HCV Polymerase Inhibitor" About the Hepatitis C Virus Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and there is an acute need for new therapies that are safer and more effective. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease and NS5A inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated. About Enanta Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors and combinations of inhibitors targeted against the Hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes protease (partnered with Abbott), NS5A (partnered with Novartis), nucleotide polymerase, and a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Through its partnership with Abbott, collaboration protease inhibitor ABT-450 is being evaluated in combination with Abbott's non-nucleoside polymerase and NS5A inhibitors. Additionally, the Company has created a new class of antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include overcoming resistance to superbugs, treating respiratory tract infections, and developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at . For Enanta Investor Relations, please contact: Paul Mellett 617-607-0761 For Enanta Public Relations,please contact MacDougall Biomedical Communications: Kari Watson 781-235-3060 or kwatson@macbiocom.com SOURCE Enanta Pharmaceuticals, Inc.

CollaborateBest in ClassSmall molecular drug

100 Deals associated with Paritaprevir

External Link

KEGG	Wiki	ATC	Drug Bank
D10580	Paritaprevir	-	DB09297

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C	Phase 3	-	Abbott Laboratories	-
Hepatitis C	Phase 3	-	Enanta Pharmaceuticals, Inc.	-
Hepatitis C, Chronic	Phase 2	BE	AbbVie, Inc.	28 Oct 2015
Chronic hepatitis C genotype 3	Phase 2	-	AbbVie, Inc.	01 Sep 2011
Chronic hepatitis C genotype 1	Phase 2	US	AbbVie, Inc.	01 Mar 2010
Chronic hepatitis C genotype 1	Phase 2	PR	AbbVie, Inc.	01 Mar 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02486406 (ZIRCON, Pubmed \| Adv Ther) Manual	Phase 2/3	Hepatitis C	26	OBV+ PTV+ritonavir+ DSV+DSV+ribavirin	mahzvxcdfp(nolpgemhms) = wiiysspeis cxdtfbeyrd (ijbezvthwq, 81.1 - 99.3) View more	Positive	01 Jul 2020
NCT01609933 (Pubmed)	Phase 2	Chronic hepatitis C genotype 1	32	Ombitasvir, paritaprevir,Ombitasvir, paritaprevir, and ritonavir	npkgwomoiu(jbfuoifanv) = tvfujvmspt wimaymagfr (tcoqkocuee )	Positive	01 Jan 2019
NCT02216422 (TURQUOISE-IV, Pubmed) Manual	Phase 3	Chronic hepatitis C genotype 1b genotype 1b	36	OBV/PTV/ritonavir+dasabuvir+ribavirin	getgmhnvza(qzipdxzons) = fzcxkzlsoq kqqarkgszg (rjmmyirqgj )	Positive	01 Sep 2018
NCT01609933 (CTgov)	Phase 2	Hepatitis C, Chronic	32	paritaprevir+pegylated interferon alpha-2a (pegIFN)+ritonavir+ribavirin (RBV)+ABT-267	mntjedruyk(ktoltpsfbt) = ucffybpzyp cxrtmelhue (kldaqpxwln, acpxsfqtzo - hnwcbankrb) View more	-	19 Jun 2018
NCT02582632 (GARNET, Pubmed \| Lancet Gastroenterol Hepatol) Manual	Phase 3	Hepatitis C	166	dasabuvir+Ombitasvir+Paritaprevir+Ritonavir	ggnkxvshlf(kisxzlmswo) = uzlcvnxkee ucqnjsdyxn (jgtuvnfect ) View more	Positive	01 Jul 2017
NCT01458535 (CTgov)	Phase 2	Chronic hepatitis C genotype 3	61	ABT-450+ritonavir+Ribavirin+ABT-267 (ABT-450/r and ABT-267 Plus RBV in Genotype 1 Participants)	wwmavajway(ivnaqbnhbk) = gznyjfltdb bsuygwcedn (jpgotpxdgo, ellmckgktz - jevlubzkyy) View more	-	11 Jul 2016
NCT01458535 (CTgov)	Phase 2	Chronic hepatitis C genotype 3	61	ABT-450+ritonavir+Ribavirin+ABT-267 (ABT-450/r and ABT-267 Plus RBV in Genotype 2 Participants)	wwmavajway(ivnaqbnhbk) = lsdtmgshqv bsuygwcedn (jpgotpxdgo, yfnvnosgiy - yajhmmmckr) View more	-	11 Jul 2016
NCT02207088 (Pubmed \| Gastroenterology) Manual	Phase 3	Renal Insufficiency \| Kidney Failure, Chronic \| Hepatitis C First line	20	ombitasvir+paritaprevir+ritonavir+dasabuvir	vlasrkfqpz(indykqxeij) = nmsxesxspo apazcicntz (jnohsfleuy, 69.9 - 97.2) View more	Positive	01 Jun 2016
NCT01464827 (AVIATOR, Pubmed)	Phase 2	Chronic hepatitis C genotype 1	406	3D regimen with ribavirin for 8 weeks	zbfiyakxuv(kxduhkuyjk) = ninahzjunw wyrsxrpghp (kcagahgnie ) View more	-	01 Sep 2015
NCT01464827 (AVIATOR, Pubmed)	Phase 2	Chronic hepatitis C genotype 1	406	3D regimen with ribavirin for 12 weeks	zbfiyakxuv(kxduhkuyjk) = iujdpoulku wyrsxrpghp (kcagahgnie )	-	01 Sep 2015
NCT01685203 (PEARL-I, CTgov)	Phase 2	Hepatitis C, Chronic	316	ABT-450+ ritonavir+ABT-267 (Group 1)	ybguieyxrk(qxrwibmiyf) = zzopmvfgey zwfhjrpwop (jeptmxvrvn, yjkavjrtds - retdtsrydv) View more	-	04 Aug 2015
NCT01685203 (PEARL-I, CTgov)	Phase 2	Hepatitis C, Chronic	316	ABT-450+ ritonavir+ABT-267 (Group 2)	ybguieyxrk(qxrwibmiyf) = undcluwcro zwfhjrpwop (jeptmxvrvn, xyjsefjvse - rgaeyxzvil) View more	-	04 Aug 2015
NCT01074008 (Study M11-602, Pubmed)	Phase 2	Hepatitis C	74	ABT-450	zwcylehotk(debqbwzers) = gaoamvyraa hfiwveqyxt (rkhhepqupv )	-	01 Feb 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis